DANG [E-COMMERCE CHINA DANGDANG] S-8 POS:
[]
DANG [E-COMMERCE CHINA DANGDANG] 6-K: (Original Filing)
[E-Commerce China Dangdang Inc. Announces Completion of Merger Under the terms of the merger agreement, which was approved by the Company’s shareholders at an extraordinary general meeting held on September 12, 2016, at the effective time of the merger (the “Effective Time”), all of the Class A common shares and Class B common shares, par value $0.0001 per share (each,] []
DANG [E-COMMERCE CHINA DANGDANG] 6-K: E-Commerce China Dangdang Inc. Announces Completion of Merger
[E-Commerce China Dangdang Inc. Announces Completion of Merger Under the terms of the merger agreement, which was approved by the Company’s shareholders at an extraordinary general meeting held on September 12, 2016, at the effective time of the merger (the “Effective Time”), all of the Class A common shares and Class B common shares, par value $0.0001 per share (each,] []
SCOK [Hongli Clean Energy Technologies] PRE 14C: (Original Filing)
[SCHEDULE 14C INFORMATION Check the appropriate box: x ¨ 14c-5(d)(2)) ¨ Hongli Clean Energy Technologies Corp. Payment of Filing Fee (Check the appropriate box): x ¨ Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 4) Proposed]
SCOK [Hongli Clean Energy Technologies] PRE 14C: SCHEDULE 14C INFORMATION Check the appropriate box: x
[SCHEDULE 14C INFORMATION Check the appropriate box: x ¨ 14c-5(d)(2)) ¨ Hongli Clean Energy Technologies Corp. Payment of Filing Fee (Check the appropriate box): x ¨ Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 4) Proposed]
CBPO [China Biologic Products] 8-K: (Original Filing)
[China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug] []
CBPO [China Biologic Products] 8-K: China Biologic Receives CFDA Clinical Trial Approval for
[China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug] []
LITB [LightInTheBox] 6-K: (Original Filing)
[LightInTheBox Reports Second Quarter 2016 Financial Results Conference Call to be Held at 8:00AM ET on September 19, 2016 Beijing, China, September 19, 2016 - LightInTheBox Holding Co., Ltd. (NYSE: LITB) (LightInTheBox or the Company), a global online retail company that delivers products directly to consumers around the world, today announced its unaudited financial results for the second quarter of] [TABLE OF CONTENTS 2 LIGHTINTHEBOX HOLDING CO., LTD.]
